Thomas Evers

1.5k total citations
57 papers, 1.0k citations indexed

About

Thomas Evers is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Surgery. According to data from OpenAlex, Thomas Evers has authored 57 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Cardiology and Cardiovascular Medicine, 19 papers in Economics and Econometrics and 7 papers in Surgery. Recurrent topics in Thomas Evers's work include Health Systems, Economic Evaluations, Quality of Life (19 papers), Atrial Fibrillation Management and Outcomes (16 papers) and Heart Failure Treatment and Management (11 papers). Thomas Evers is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (19 papers), Atrial Fibrillation Management and Outcomes (16 papers) and Heart Failure Treatment and Management (11 papers). Thomas Evers collaborates with scholars based in Germany, United States and United Kingdom. Thomas Evers's co-authors include Sebastian Schneeweiß, Shirley Wang, Rishi Desai, Jan Beyer‐Westendorf, B. Ehlken, Muthiah Vaduganathan, Craig I Coleman, Paul Cullen, D. Petzinna and H. Schulte and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Thomas Evers

53 papers receiving 989 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Evers Germany 18 632 152 142 128 125 57 1.0k
Elena Birman-Deych United States 6 743 1.2× 215 1.4× 133 0.9× 67 0.5× 298 2.4× 7 1.5k
Erin R. Weeda United States 14 221 0.3× 154 1.0× 75 0.5× 121 0.9× 102 0.8× 83 918
Gang Fang United States 20 408 0.6× 113 0.7× 212 1.5× 67 0.5× 80 0.6× 38 961
Shun Fu Lee Canada 14 418 0.7× 43 0.3× 90 0.6× 129 1.0× 126 1.0× 47 863
Hernan Polo Friz Italy 14 500 0.8× 188 1.2× 39 0.3× 56 0.4× 116 0.9× 42 921
Michael P. Dorsch United States 20 619 1.0× 114 0.8× 76 0.5× 137 1.1× 56 0.4× 104 1.3k
Rashmee U. Shah United States 24 1.1k 1.7× 35 0.2× 201 1.4× 81 0.6× 146 1.2× 65 1.7k
Philip Tideman Australia 17 641 1.0× 55 0.4× 112 0.8× 116 0.9× 113 0.9× 37 1.2k
Alok Kapoor United States 13 176 0.3× 77 0.5× 86 0.6× 104 0.8× 71 0.6× 53 582
Iván Díaz United States 22 325 0.5× 61 0.4× 153 1.1× 32 0.3× 329 2.6× 97 1.3k

Countries citing papers authored by Thomas Evers

Since Specialization
Citations

This map shows the geographic impact of Thomas Evers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Evers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Evers more than expected).

Fields of papers citing papers by Thomas Evers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Evers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Evers. The network helps show where Thomas Evers may publish in the future.

Co-authorship network of co-authors of Thomas Evers

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Evers. A scholar is included among the top collaborators of Thomas Evers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Evers. Thomas Evers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ohlmeier, Christoph, Thomas Evers, Stefan Herrmann, et al.. (2024). Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany. European Journal of Clinical Pharmacology. 80(6). 931–940. 10 indexed citations
2.
Bamber, Luke, et al.. (2023). Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study. Patient Preference and Adherence. Volume 17. 1181–1196. 1 indexed citations
3.
Rao, Vishal N., Derek D. Cyr, Lisa Wruck, et al.. (2023). Electronic health record characterization and outcomes of heart failure with preserved ejection fraction. American Heart Journal. 263. 1–14. 1 indexed citations
4.
Folkerts, Kerstin, Natalia Petruski‐Ivleva, Michael Blankenburg, et al.. (2021). Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database. Mayo Clinic Proceedings. 96(4). 975–986. 37 indexed citations
5.
Schneeweiß, Sebastian, et al.. (2020). Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. SHILAP Revista de lepidopterología. 2 indexed citations
6.
Glynn, Robert J., Sebastian Schneeweiß, Kueiyu Joshua Lin, et al.. (2020). <p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p>. Clinical Epidemiology. Volume 12. 607–616. 27 indexed citations
7.
Gerlinger, Christoph, Thomas Evers, Jeremy A. Rassen, & Richard Wyss. (2020). Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile. Drugs - Real World Outcomes. 7(3). 221–227. 3 indexed citations
8.
9.
10.
Semchuk, William, et al.. (2013). Management of Stroke Prevention in Canadian Patients with Atrial Fibrillation at Moderate to High Risk of Stroke. The Canadian Journal of Hospital Pharmacy. 66(5). 296–303. 1 indexed citations
11.
Kourlaba, Georgia, Nikos Maniadakis, George Andrikopoulos, et al.. (2012). PCV49 Economic Evaluation of Rivaroxaban in Stroke Prevention Among Patients With Atrial Fibrillation in Greece. Value in Health. 15(7). A371–A371. 1 indexed citations
12.
13.
Asukai, Yumi, et al.. (2012). PCV73 Prevention of Stroke in Patients With Atrial Fibrillation: Cost-Utility Analysis of Rivaroxaban Versus Warfarin in Slovakia. Value in Health. 15(7). A375–A375. 3 indexed citations
14.
15.
Lamotte, Mark, Lieven Annemans, Thomas Evers, & Maria Kubin. (2006). A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. PharmacoEconomics. 24(2). 155–169. 26 indexed citations
16.
Lamotte, Mark, et al.. (2006). Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. International Journal of Clinical Practice. 60(9). 1129–1137. 7 indexed citations
17.
Gerber, Andreas, Thomas Evers, Heinz Haverkamp, & Karl W. Lauterbach. (2006). Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction. The European Journal of Health Economics. 7(4). 247–254. 15 indexed citations
18.
Kubin, Maria, Michel Lamotte, Lieven Annemans, & Thomas Evers. (2005). The health economic value of Aspirin in the primary prevention of cardiovascular disease in diabetic patients in four European countries. Diabetologia. 48. 331. 1 indexed citations
19.
Assmann, Gerd, Paul Cullen, Thomas Evers, D. Petzinna, & H. Schulte. (2005). Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. European Heart Journal. 26(20). 2120–2126. 108 indexed citations
20.
Hellmich, Martin, Thomas Evers, Maria Kubin, et al.. (2005). Development and Validation of a Risk Score for Somatic Erectile Dysfunction: Combined Results from Three Cross-Sectional Surveys. European Urology. 48(3). 495–502. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elena Birman-Deych Breakdown of academic impact, for papers by Erin R. Weeda Breakdown of academic impact, for papers by Gang Fang Breakdown of academic impact, for papers by Shun Fu Lee Breakdown of academic impact, for papers by Hernan Polo Friz Breakdown of academic impact, for papers by Michael P. Dorsch Breakdown of academic impact, for papers by Rashmee U. Shah Breakdown of academic impact, for papers by Philip Tideman Breakdown of academic impact, for papers by Alok Kapoor Breakdown of academic impact, for papers by Iván Díaz
Rankless by CCL
2026